Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Acupuncture on Nausea, Vomiting, Pain, PGE2 and IL 6 in Septorhinoplasty

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04009070
Recruitment Status : Recruiting
First Posted : July 4, 2019
Last Update Posted : July 8, 2019
Sponsor:
Information provided by (Responsible Party):
Yavuz Orak, Kahramanmaras Sutcu Imam University

Brief Summary:
Acupuncture has emerged in China about 2,000 years ago and is one of the oldest medical procedures in the world.Later acupuncture was introduced to other regions such as Asia, Europe and the United States.The most extensive use of acupuncture is for pain relief.Especially, postoperative nausea and vomiting have been studied.In one study, PC6 (approximately two cm above the midline of the wrist line) showed antiemetic effect, with the addition of other acupuncture points, it proved to have a protective effect in the treatment of postoperative nausea and vomiting.ST36 (Approximately 1-2 cm laterally from the tuberocyte tibia) is an acupuncture point used in the treatment of diseases such as inflammation, acute pain, hypertension and gastrointestinal disorders.

Condition or disease Intervention/treatment Phase
Pain Acupuncture Device: Acupuncture Pres Needle: 0.22x1.5 mm needle Not Applicable

Detailed Description:

Patients will be determined as Group A: Acukupuncture group and Group C as Control group and 35 patients will be included in the study. Both groups will be given an intravenous (i.v) route in the preoperative patient room, PGE2, IL 6 will be taken for blood and 0.09% NaCl will be started. Group A preoperatively, 24 hours prior to bilateral PC6 (approximately two cm above the midline of the wrist line) and ST 36 (approximately 1-2 cm laterally from the Tibia) to be applied to the press needle (0.22x1.3 mm) and the tape (Needle Press will remain for 24 hours after surgery. Electrocardiography (ECG), noninvasive blood pressure (SBP-DBP), and peripheral arterial oxygen saturation (SpO2) monitoring will be applied to the patients. In the induction of anesthesia, Pentotal 5 mg / kg, Fentanyl 0.5 mcg / kg, and rocuronium 0.6 mg / kg will be used. Anesthesia maintenance will be provided with a 2% concentration of sevoflurane, 50% nitrous oxide (N2O) and 50% oxygen (O2) mixture and appropriately intubated. Patients will be recorded with systolic blood pressure (SBP), diastolic blood pressure (heart failure), heart rate (HR), mean arterial pressure (MAP) and SpO2, 5, 15, 30, 60, 120 minutes (min) after induction.

Patients in Group A and Group C had a saturation value of 97% or more, and exhaled if breathing effort was sufficient. Atropine and neostigmine will be used to neutralize muscle relaxants. Contramal 1mg / kg will be applied to the patients as standard by 20 minutes before the end of surgery. Following the termination of the surgical intervention, the anesthesia gases will be cut and 100% O2 will be inhaled with the mask until all the cases are compiled. 5.dk follow-up and extubation period of the patients will be taken to the postoperative rest room after being followed up on the operating table. 30. Min follow-up will be sent to their services after being done here. Postoperative 60 min, 3 h, 6 h, 12 h, 24 h, sore throat, nausea, vomiting, cough, itching, dysphagia, sore throat and analgesic needs, whether pain, assessment will be made. VAS score will be used to evaluate pain. Paracetamol will be applied to all patients when analgesia needs. At 24 hours postoperatively, blood will be taken to look for PGE2 and IL6 values.Preoperative and postoperative PGE2 and IL 6 values will be compared between the groups of the acupuncture group and the control group.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Group A: Acupuncture Group Group C: Control Group
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Effect of Acupuncture on Nausea, Vomiting, Pain, PGE2 and IL 6 in Septorhinoplasty Operations; Prospective, Randomized, Controlled Study
Actual Study Start Date : July 5, 2019
Estimated Primary Completion Date : October 1, 2019
Estimated Study Completion Date : November 1, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Acupuncture

Group A: Acupuncture group:Group A: Acupunctur will be applied to the Acupunctur group 24 hours prior to bilateral PC6 (approximately two cm above the midline of the wrist line) and ST 36 (approximately 1-2 cm laterally on the tibia) . The tape (Needle Press) will stay for 24 hours.

Needle Press: Pres Needle: 0.22x1.5 mm needle

Device: Acupuncture Pres Needle: 0.22x1.5 mm needle
Acupunctur group; Acupunctur preoperatively 24 hours before bilateral PC6 (approximately two cm above the midline of the wrist line) and ST 36 (approximately 1-2 cm laterally from the tuberocyte tibia). The tape (Needle Press) will remain for 24 hours after surgery.

No Intervention: Control Group
Group C: Control group



Primary Outcome Measures :
  1. Change Pain Scores [ Time Frame: 5 minute,30 minute, 60 minute, 3 hours, 6 hours, 12 hours, 24 hours after the operation ]
    VAS (Visual analog scale) Score. from 1 to 10 , 0: No pain, 10: 10 pain that can not be tolerated

  2. PG E2 [ Time Frame: Change from baseline and concentration of preoperativ and postoperative values at 24.hours ]
    To evaluate the impact on the circulating levels of PG E2 ng/ml

  3. IL 6 [ Time Frame: Change from baseline and concentration of preoperativ and postoperative values at 24.hours ]
    To evaluate the impact on the circulating levels of IL 6 ng/ml

  4. Nause and Vomiting [ Time Frame: After operation at 5 minutes, 30 minutes, 60 minutes,3 hours, 6 hours, 12 hours, 24 hours ]
    Yes or No Nause and vomiting


Secondary Outcome Measures :
  1. Blood Pressure [ Time Frame: During operation at 5 minute, 15 minutes, 30 minutes, 60 minutes, 120 minutes and After operation at 5 minutes, 30 minutes, 60 minutes,3 hours, 6 hours, 12 hours, 24 hours after operation ]
    Systolic blood pressue mmHg , diastolic blood pressure mmHg, mean arterial pressure mmHg,

  2. Heart rate [ Time Frame: During operation at 5 minute, 15 minutes, 30 minutes, 60 minutes, 120 minutes and After operation at 5 minutes, 30 minutes, 60 minutes,3 hours, 6 hours, 12 hours, 24 hours ]
    heart rate ,

  3. Change of Itching, cough, sore throat, difficulty in swallowing [ Time Frame: Do Patients have any Itching, cough, sore throat, difficulty in swallowing in 5 minute,30 minute, 60 minute, 3 hours, 6 hours, 12 hours, 24 hours after operation ]
    it will be asked if there are Itching, cough, sore throat, difficulty in swallowing.more in which group.

  4. oxygen follow-up [ Time Frame: at 5 minute, 15 minutes, 30 minutes, 60 minutes, 120 minutes during ]
    oxygen saturation

  5. oxygen follow-up [ Time Frame: 30 minutes, 60 minutes,3 hours, 6 hours, 12 hours, 24 hours after the operation, ]
    oxygen saturation



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ASA I-II group
  • Aged 18-75
  • Volunteer to participate in the study
  • Conscious patients.

Exclusion Criteria:

  • Not wanting to participate
  • Unconscious
  • Having a hearing and speech problem
  • Allergic disease and bleeding disorder
  • Respiratory problems

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04009070


Contacts
Layout table for location contacts
Contact: yavuz orak, md +90344 300 3434 ext 3343 dryavuzorak@hotmail.com
Contact: filiz baylan, md +90344 300 3434 ext 3392 drfilizalkan@gmail.com

Locations
Layout table for location information
Turkey
Kahramanmaras Sutcu Imam University Faculty of Medicine Recruiting
Kahramanmaraş, Onikişubat, Turkey, 251/A 46040
Contact: Yavuz Orak, md    +90 (344) 300 3434 ext 3343    dryavuzorak@hotmail.com   
Sponsors and Collaborators
Kahramanmaras Sutcu Imam University
Investigators
Layout table for investigator information
Principal Investigator: yavuz orak, md Kahramanmaraş Sutcu Imam University Faculty of Medicine

Study Data/Documents: Individual Participant Data Set  This link exits the ClinicalTrials.gov site

Layout table for additonal information
Responsible Party: Yavuz Orak, Assistant Professor, Kahramanmaras Sutcu Imam University
ClinicalTrials.gov Identifier: NCT04009070     History of Changes
Other Study ID Numbers: 2018/12-17
First Posted: July 4, 2019    Key Record Dates
Last Update Posted: July 8, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Vomiting
Signs and Symptoms, Digestive
Signs and Symptoms